Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.54 |
| ▸ | SORD | Q00796 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8401502 | 0.98 | KDM4E (0.68) | KDM4EMAPTHTR1ADRD2HTR2A | |
| SCHEMBL4558892 | 0.84 | KDM4E (0.71) | KDM4EMAPTHTR1ADRD2HTR2A | |
| SCHEMBL11637734 | 0.83 | KDM4E (0.65) | KDM4EMAPTHTR1ADRD2HTR2A | |
| SCHEMBL20428029 | 0.83 | KDM4E (0.65) | KDM4EMAPTHTR1ADRD2HTR2A | |
| SCHEMBL13591224 | 0.83 | KDM4E (0.65) | KDM4EMAPTHTR1ADRD2HTR2A | |
| SCHEMBL10845197 | 0.83 | HTR1A (0.62) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL7771352 | 0.83 | KDM4E (0.60) | KDM4EMAPTHTR1ADRD2HTR2A | |
| SCHEMBL8145185 | 0.83 | KDM4E (0.60) | KDM4EMAPTHTR1ADRD2HTR2A | |
| SCHEMBL1837722 | 0.83 | KDM4E (0.60) | KDM4EMAPTHTR1ADRD2HTR2A | |
| SCHEMBL10844660 | 0.83 | KDM4E (0.60) | KDM4EMAPTHTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4590196-A | NON-OPIATE | BRISTOL-MYERS COMPANY (US) | 1986-05-20 | — | — | US | claimed |
| US-4104388-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1978-08-01 | — | — | US | claimed |
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023135528-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2023-07-20 | — | — | WO | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20220017471-A1 | FUNCTIONALITY INDEPENDENT LABELING OF ORGANIC COMPOUNDS | UNIV SHANGHAI TECHNOLOGY (CN) | 2022-01-20 | — | — | US | disclosed |
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | disclosed |
| US-10035799-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2017154021-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LURASIDONE BASE AND ITS SALT | ZCL CHEMICALS LTD. (IN) | 2017-09-14 | — | — | WO | disclosed |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2016-08-04 | — | — | US | disclosed |
| EP-1884242-B1 | PHARMACEUTICAL COMPOSITION COMPRISING LURASIDONE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8383638-B2 | Aminobenzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383638-B2 | Aminobenzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| WO-2011084371-A1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010073255-A1 | PROCESS FOR PREPARING ZIPRASIDONE | CADILA HEALTHCARE LIMITED (IN) | 2010-07-01 | — | — | WO | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| US-4104388-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, MTNR1B | KDM4E 895/4885MAPT 574/4885HTR1A 30/4885 |
| US-20220017471-A1 | FUNCTIONALITY INDEPENDENT LABELING OF ORGANIC COMPOUNDS | PAICS, PFAS, OTC | KDM4E 2511/4885MAPT 2746/4885HTR1A 3579/4885 |
| US-10035799-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | KDM4E 1957/4885MAPT 1246/4885HTR1A 125/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | KDM4E 2085/4885MAPT 236/4885HTR1A 343/4885 |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | KDM4E 1957/4885MAPT 1246/4885HTR1A 125/4885 |
| US-10479790-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | KDM4E 1957/4885MAPT 1246/4885HTR1A 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.